An implanted shunt diverts CSF from the ventricles within the brain or the subarachnoid spaces around the brain and spinal cord to another body region where it will be absorbed. This creates an alternative route for removal of CSF which is constantly produced within the brain and usually restores the physiological balance between CSF production, flow, and absorption when one or more of these functions has been impaired. Valves contained within the shunt pathway act like on-off switches, opening when the differential pressure (DP) – i.e., the pressure difference across the valve – exceeds the valve’s opening pressure. Valves are either set to a fixed pressure or they can be adjustable from outside the body. Accessory devices may be added to the shunt to modify valve function.

The global Ventriculoperitoneal (VP) Shunt market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Ventriculoperitoneal (VP) Shunt volume and value at global level, regional level and company level. From a global perspective, this report represents overall Ventriculoperitoneal (VP) Shunt market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Sophysa
Aesculap
B. Braun Melsungen
Integra lifesciences
Medtronic
...

Segment by Regions
North America
Europe
China
Japan

Segment by Type
Fixed Pressure Valves
Variable Pressure Valves

Segment by Application
Hospitals
Clinics and Ambulatory Care centers
Laboratories
Others